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Abstract The chemical universe database GDB-13,
which enumerates 977 million organic molecules up to 13
atoms of C, N, O, S and Cl following simple chemical
stability and synthetic feasibility rules, represents a vast
reservoir for new fragments. GDB-13 was classified using
the MQN-system discussed in the preceding paper for the
analysis of PubChem fragments. Two hundred and fifty-
five subsets of GDB-13 were generated by the combina-
torial use of eight restrictive criteria, including fragment-
like (‘‘rule of three’’) and scaffold-like (no acyclic carbon
atoms) filters. Virtual screening for analogs of 15 com-
mercial drugs of 13 non-hydrogen atoms or less shows that
retrieving MQN-neighbors of a query molecule from GDB-
13 or its subsets provides on average a 38-fold enrichment
in structural analogs (Daylight-type substructure fingerprint
Tanimoto TSF [ 0.7), and a 75-fold enrichment in shape-
similar analogs (ROCS TanimotoCombo score [ 1.4). An
MQN-searchable version of GDB-13 is provided at
www.gdb.unibe.ch.
Keywords Databases  Virtual screening  Chemical
space  Enumeration  Fragments
Introduction
The discovery of innovative chemotypes is one of the key
chemical problems in small molecule drug discovery, in
particular at the level of fragments, a size range which also
includes many drugs [1–8]. Beyond all fragment-sized
molecules that are already known, such as those collected in
the public access database PubChem [9] as discussed in the
preceding paper in this issue [10], one might want to con-
sider all molecules that could ever be possibly synthesized.
Along these lines, we recently reported the enumeration of
all molecules up to a size of 13 non-hydrogen atoms fol-
lowing predefined chemical stability and synthetic feasi-
bility rules, which produced the chemical universe database
GDB-13 containing 977 million virtual molecules of C, N,
O, S, Cl [11]. This database was an extension of a previous
version GDB-11 containing 26.4 million virtual molecules
up to 11 non-hydrogen atoms of C, N, O, F [12, 13], which
was shown to provide a useful starting point for designing
bioactive synthetic ligands [14–17]. GDB-13 exceeds the
number of known molecules of similar size by several
orders of magnitude and represents a vast and mostly
unexploited reservoir for innovation [18].
The meaningful exploration of GDB-13 requires efficient
virtual screening tools to identify compounds of biological
interest for synthesis and testing. At present however such
exploration is limited by the currently available virtual
screening methods, which typically process at most a few
million structures within resonable computing time. To
address this limitation, we recently reported a molecule
classification method for large databases called the MQN-
system [19]. This system places organic molecules in a
chemical space [18, 20–22] on the basis of 42 integer value
descriptors for structural and topological features, called
MQNs (Table 1). The MQNs can be determined visually
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from the structural formula by anyone with basic knowl-
edge in organic chemistry, such that MQN-space is readily
accessible to non-specialists. The analysis produces mean-
ingful overviews of large molecular databases such as ZINC
[23] and PubChem [9] as color-coded maps derived from
principal component analysis (PCA) of the MQN data [24].
Furthermore, the MQN-system computes very fast and
performs remarkably well in virtual screening as exempli-
fied previously for the enrichment of bioactives from the
DUD dataset from the entire PubChem database [24, 25].
Herein we report the visualisation and an efficient vir-
tual screening approach for the entire GDB-13 database
based on the MQN-system. The database was subdivided
into 255 subsets defined by the combinatorial use of eight
different criteria limiting structural complexity and func-
tional groups. MQN nearest-neighbour searches performed
on the entire GDB-13 or on any of its subsets are shown to
rapidly identify structural and shape analogs of any query
molecule. Structural similarity between two compounds is
typically measured by the substructure fingerprint Thus,
scoring MQN-nearest neighbors of a query molecule by
substructure fingerprint (SF) similarity (measured by the
Tanimoto value TSF) [26] or by shape similarity (measured
by the ROCS TanimotoCombo score) [27] as indicators of
bioactivity probability shows that MQN-nearest neighbors
are strongly enriched in structural analogs and shape-sim-
ilar analogs of the query molecule. An MQN-searchable
version of GDB-13 is provided at www.gdb.unibe.ch, and
should greatly facilitate the exploitation of GDB-13 for the
identification of new medicinally relevant small molecules
for synthesis and testing.
Results and discussion
Visualisation of GDB-13
The 42 MQN-values were obtained for 975,821,779 mole-
cules in GDB-13, resulting in 37,249,813 different MQN-
combinations. The most occupied MQN-bin contained
12,589 molecules, while 4,959,920 MQN-bins contained
only one molecule (Fig. 1) [19]. Principal component
analysis (PCA) was performed to gain an insight into the
data structure. PC1 (51%) represented mostly structural
rigidity, with strongly positive loadings in cyclic descriptors
e.g. cyclic single bonds (csb) and strongly negative loadings
in acyclic descriptors e.g. acyclic single bonds (asb). PC2
(12%) reflected H-bonding behaviour and polarity, with
strong positive loadings in hydrogen bond acceptors (hba,
hbam), and strongly negative loadings in hydrogen bond
donors (hbdm) and carbon counts (c) (Fig. 2).
Table 1 The 42 molecular quantum numbers (MQNs)
Atom counts (12) Bond counts (7)
c Carbon asb Acyclic single bonds
f Fluorine adb Acyclic double bonds
cl Chlorine atb Acyclic triple bonds
br Bromine csb Cyclic single bonds
i Iodine cdb Cyclic double bonds
s Sulphur ctb Cyclic triple bonds
p Phosphorous rbc Rotatable bond count
an Acyclic nitrogen Topology countsb (17)
cn Cyclic nitrogen asv Acyclic monovalent nodes
ao Acyclic oxygen adv Acyclic divalent nodes
co Cyclic oxygen atv Acyclic trivalent nodes
hac Heavy atom count aqv Acyclic tetravalent nodes
Polarity countsa (6) cdv Cyclic divalent nodes
hbam H-bond acceptor sites ctv Cyclic trivalent nodes
hba H-bond acceptor atoms cqv Cyclic tetravalent nodes
hbdm H-bond donor sites r3 3-membered rings
hbd H-bond donor atoms r4 4-membered rings
neg Negative charges r5 5-membered rings
pos Positive charges r6 6-membered rings
r7 7-membered rings
r8 8-membered rings
r9 9-membered rings
rg10 C10 membered rings
afr Atoms shared by fused rings
bfr Bonds shared by fused rings
a Polarity counts consider the ionization state predicted for the
physiological pH = 7.4. hbam counts lone pairs on H-bond acceptor
atoms and hbdm counts H-atoms on H-bond donating atoms
b All topology counts refer to the smallest set of smallest rings. afr
and bfr count atoms repectively bonds shared by at least two rings
Fig. 1 Distribution of MQN-bins as a function of bin-occupancy for
GDB-13
638 J Comput Aided Mol Des (2011) 25:637–647
123
In the (PC1, PC2) plane, GDB-13 appears as a series of
overlapping vertically elongated islands, each containing
compounds with increasing numbers of rings and ring
atoms (Fig. 3). Polar molecules with a high proportion of
H-bond acceptor atoms occupy the northern portion of the
map, while apolar molecules with mostly carbon atoms
occupy the south. This layout corresponds to the (PC1,
PC3) view obtained in the analysis of the PubChem frag-
ments presented in the preceding paper. Indeed molecular
size, which determined PC2 in the PubChem fragment
analysis, does not significantly impact variance in GDB-13
because 87% of the database contains molecules of exactly
13 non-hydrogen atoms.
Subsets of GDB-13
GDB-13 is produced from an exhaustive enumeration
starting from mathematical graphs [28] using filters
removing many unstable and/or synthetically undesirable
functional groups [11], which circumvents some of the
limitations of the enumeration algorithms used in com-
puter-aided structure elucidation [29, 30]. Despite of this
careful selection of functional groups, the database still
contains a large fraction of problematic molecules in the
perspective of synthetic and medicinal chemistry [31].
For example, 35% of GDB-13 molecules contain one or
more non-aromatic N–N or N–O bond (in an oxime or
hydrazone), 29% contain at least one ester, aldehyde,
carbonate, sulfate, epoxide or aziridine, 63% contain at
least one non-aromatic carbon–carbon double or triple
bond, and 54% contain at least one 3- or 4-membered
ring.
To facilitate the identification of molecules with the
least problematic structural features and the most relevance
for drug discovery in GDB-13, subsets A–H were formed
by removing non-aromatic cyclic and acyclic heteroatom-
heteroatom bonds (subsets A and B), problematic func-
tional groups (subset C), non-aromatic cyclic and acyclic
CC-unsaturations (subsets D and E), small cycles (subset
F). Further restrictions were taken by applying the ‘‘rule of
three’’ for fragment-likeness (subset G) [32], and finally
excluding acyclic carbon atoms (defined here as scaffold-
likeness, subset H) (Table 2). The combinatorial applica-
tion of these criteria defined 255 subsets of decreasing size,
with the smallest subset ABCDEFGH applying all criteria
cumulatively containing 1.47 million structures, which is
still 2.4-fold larger than the 619,675 molecules of that size
available in public databases (Fig. 4).
Virtual screening
GDB-13 is far too large for applying advanced virtual
screening tools such as docking or shape-based analyses,
which are too resource intensive to perform on more than a
few million structures [33]. Therefore a virtual screening
strategy for GDB-13 should start with a first rapid
enrichment step. We showed recently that distances
between molecules in MQN-space measured by the city-
block distance (CBDMQN) provide a useful similarity
measure for virtual screening [24, 34, 35]. The CBDMQN
between two compounds is simply the sum of the 42
absolute values of the differences between MQN-values
across the 42 pairs. Ranking PubChem by CBDMQN rela-
tive to a reference bioactive compound was shown to
strongly enrich other actives for the same target for most of
the 40 classes listed in the DUD-dataset [24, 25]. To test if
a similar MQN-based enrichment strategy would be
applicable for GDB-13, we searched for analogs of 15
known reference bioactive compounds of 12 or 13 non-
hydrogen atoms. An MQN-subset of 150,000 structures
was assembled containing the 10,000 MQN-nearest
neighbors of each of these 15 bioactive compounds in
GDB-13. We then used scoring functions to estimate bio-
activity probability in place of actual bioactivity mea-
surements because synthesizing and testing any significant
fraction of GDB-13 was not a practical option.
Fig. 2 Loadings of the first
three principal components in
the PCA of MQNs for GDB-13.
MQNs are sorted by decreasing
value of PC1 (black bar). See
Table 1 for listing of MQNs
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Fig. 3 MQN-maps of the (PC1, PC2) plane for GDB-13. PC1 codes
for molecular rigidity and PC2 codes for polarity, see Fig. 2. The
surface is hashed in 1,000 9 700 pixels. Each pixel is colored
according to the occupancy or to the average value in that pixel,
following the values indicated on the map on the corresponding color.
Saturation to grey indicates the standard deviation for that value in the
pixel up to ± 1 (rings), ± 2.1 (ring atoms and H-bond acceptors),
and ± 2.8 (carbon atoms). The lightness scale (fading to white)
encodes the occupancy in a logarithmic scale between 0 (white) and
200 (full color). For the category map molecules were assigned to
categories in the priority order heteroaromatic (red) [aromatic
(purple, not visible) [fused heterocycles (blue) [fused carbocycles
(cyan) [heterocycles (green) [carbocycles (green-yellow) [heteroa-
cyclic compounds (acyclic molecules with interrupted carbon chain,
yellow) [carboacyclic compounds (acyclic molecules with continu-
ous carbon chain, orange), and pixels were colored following the
most frequent category in that pixel with fading to grey indicating
category purity in the pixel
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GDB molecules were first scored using the Tanimoto
similarity coefficient of a 1,024-bit Daylight-type sub-
structure fingerprint (TSF) [26]. Substructure fingerprints
are binary fingerprints in which bits are turned on when-
ever a particular substructure is present in a molecule, with
substructures defined as groups of atoms connected by
bonds up to a given maximum topological length, in our
case up to 7 bonds. Therefore, the similarity coefficient TSF
reflects structural similarity but is strongly correlated with
bioactivity because structural analogs often share similar
bioactivities. The TSF values of all 977 million GDB-13
molecules to each of the 15 reference bioactive compounds
was computed. A threshold value of TSF [ 0.7 was used for
hit identification by structural similarity, which gave a hit
rate of 0.12% across the entire GDB-13. Similar values
were observed in the different subsets A–H (hit
rate = 0.14 ± 0.05% across the eight subsets), indicating
that substructure limitations had relatively little impact on
the hit rate. Interestingly, the MQN-nearest neighbor subset
showed a hit rate of 4.5%, indicating that MQN-nearest
neighbours were enriched 38-fold for high similarity ana-
logs over the entire database (Table 3).
Table 2 Subsets of GDB-13
Criteria Subset Size Cumulated Size
GDB-13 – 975,821,779 – –
No cyclic HetHet Bonda A 801,013,244 – –
No acyclic HetHet Bondb B 779,957,069 AB 635,647,478
Stable FGc C 693,944,404 ABC 441,084,370
No cyclic C=C and C:C bondsd D 662,075,045 ABCD 277,628,675
No acyclic C=C and C:C bondse E 565,872,718 ABCDE 140,606,518
No small ringsf F 449,553,758 ABCDEF 43,729,989
Fragment-likeg G 353,200,314 ABCDEFG 12,899,741
Scaffold-likeh H 77,489,370 ABCDEFGH 1,470,284
a excludes non-aromatic cyclic NN and NO bonds
b excludes acyclic NN and NO bonds, mostly from oximes and hydrazones
c excludes aldehydes, esters, carbonates, sulfates, epoxides, aziridines
d excludes non-aromatic CC double and triple bonds inside cycles
e excludes acyclic CC double and triple bonds
f excludes three- and four-membered rings
g ‘‘rule of 3’’ according to Congreve [32]
h excludes acyclic carbon atoms
Fig. 4 Size of the 255 GDB-13 subsets obtained by the combinatorial
use of criteria A–H (Table 2). Subsets are ordered by decreasing size.
Blue bars: pure subsets (one criterion only). Red bars: cumulated
subsets (one to eight criteria). Subset criteria are shown in the bar
code below each point. Each line of the bar code corresponds to one
of the criteria A through H as indicated at left in the upper plot
Table 3 Structural similarity scores of GDB-13 and its subsets rel-
ative to 15 reference bioactive compounds
Subset Sizea TSF(max) [ 0.7
b %
GDB-13 975,821,779 1,171,324 0.12
A 801,013,244 1,171,324 0.15
B 779,957,069 1,171,258 0.15
C 693,944,404 1,120,167 0.16
D 662,075,045 1,171,272 0.18
E 565,872,718 1,169,816 0.21
F 449,553,758 188,036 0.04
G 353,200,314 592,208 0.17
H 77,489,370 61,306 0.079
Top MQNsc 150,000 6,748 4.5
a see also Table 2
b maximum TSF value against the 15 bioactive compounds. TSF is the
Tanimoto similarity coefficient for a 1,024-bit Daylight-type sub-
structure fingerprint
c containing the 10,000 MQN-nearest neighbors of each of the 15
reference bioactive compounds
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In a second approach, GDB-13 and its subsets were
scored using the ROCS TanimotoCombo score. The ROCS
(Rapid Overlay of Chemical Structures) TanimotoCombo
score measures the similarity between 3D shapes of mol-
ecules by maximizing an overlap function between
molecular shapes, considering these shapes as continuous
functions constructed from atom-centered electrostatic and
volume Gaussians [27]. The score is maximized by com-
paring various conformers of both query and reference
molecule. This 3D shape-based approach is well-validated
for ligand-based virtual screening [36]. ROCS was applied
to search for shape-similar compounds of each of the 15
selected bioactive compounds among four different sets:
(1) 10,000 randomly selected compounds from GDB-13, or
(2) from subset ABCDE (Table 1), (3) 10,000 MQN-
nearest neighbors of the respective bioactive compound
taken from GDB-13, or (4) from subset ABCDE. For each
structure, all possible diastereoisomers were generated and
Fig. 5 Gaussian distribution of
ROCS scores in ranking various
subsets. Green line: 10,000
randomly selected compounds
from GDB-13. Blue line: 10,000
randomly selected compounds
from subset ABCDE. Black
line: 10,000 MQN-nearest
neighbors of the respective
bioactive compound taken from
GDB-13. Red line: 10,000
MQN-nearest neighbors of the
respective bioactive compound
taken from subset ABCDE
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the score of the highest scoring stereoisomer was retained.
In each case a Gaussian distribution of ROCS scores was
observed (Fig. 5). Strikingly, the MQN-nearest neighbor
series (3) and (4) ranked on average 0.29 ± 0.06 units
higher than the non-MQN selected series (1) and (2)
(Fig. 6). On average 22 ± 11% of each MQN-nearest
neighbor subset (3) and (4) scored higher than 1.4, which
can be considered as an indicator of similar bioactivity
[37]. By comparison the random selections (1) and (2)
contained only 0.29 ± 0.24% of compounds with
ROCS [ 1.4. The MQN-nearest neighbors thus contained
75-fold more high-ROCS compounds than the random
selection.
A closer analysis of the TSF and ROCS scores as a
function of CBDMQN from the reference drugs showed that
MQN-neighbors (CBDMQN B 15) consistently provided
many high TSF and high ROCS scoring compounds, while
structures at larger MQN-distance (CBDMQN [ 15) had
generally low scores (Fig. 7). The TSF and ROCS scores
were however only weakly correlated. The ‘‘high-ROCS,
low TSF’’ compounds are of particular interest since these
represent scaffold-hopping analogs [38]. Examples of
analogs with high scores with only one of the similarity
measures are shown in Fig. 8. Note that these examples
were taken mostly from subset ABCDE, which excludes in
particular non-aromatic CC unsaturations (criteria DE) and
thereby avoids compounds with cyclohexadiene and
cyclopentadiene analogs of aromatic rings. Such cyclic
dienes are indeed highly similar in shape to aromatic rings,
but are not advisable as synthetic targets due to their
reactivity, in particular towards oxidative aromatization
(cyclohexadienes), electrocyclic isomerization or dimer-
ization (cyclopentadienes).
Conclusion
The chemical universe database GDB-13 was analyzed by
MQN and subdivided into 255 subsets by the combina-
torial use of eight different restrictive criteria eliminating
problematic functional groups and structural elements.
Virtual screening for analogs of fifteen bioactive com-
pounds of 12 or 13 non-hydrogen atoms showed that
selection of MQN-nearest neighbors of any query mole-
cule (using CBDMQN as distance measure) provides
subsets that are enriched in high-scoring compounds in
terms of both structural similarity (TSF) and shape simi-
larity (ROCS TanimotoCombo score). The automatic
retrieval of MQN-nearest neighbors from GDB-13 or its
subsets is facilitated by a search tool available at
www.gdb.unibe.ch. The method should greatly facilitate
the exploitation of GDB-13 for the identification of new
medicinally relevant small molecules for synthesis and
testing.
Methods
MQNs
MQNs were calculated using the previously reported cal-
culator source code (Supporting Information in Ref. [19])
Fig. 6 Shape similarity scores of GDB-13 and its subsets against
analogs of 15 bioactive compounds. ‘‘Floating bar’’ plot of max
ROCS TanimotoCombo score showing in each case the the full width
at half maximum range (FWHM, corresponds average ± 1.177
stddev for (1) 10,000 compounds randomly selected from GDB-13
(white bars); (2) 10,000 compounds randomly selected from subset
ABCDE (light grey bars); (3) 10,000 MQN-nearest neighbors from
GDB-13 (dark grey bars); (4) 10,000 MQN-nearest neighbors from
subset ABCDE (black bars)
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written in Java using the JChem library from Chemaxon,
Ltd. Prior to MQN-calculation, the ionization state of each
structure was adjusted to pH 7.4 using the JChem API.
PCA [39] was done by using an in-house developed Java
application using Jsci (http://jsci.sourceforge.net). The
source code is based on the tutorial of Lindsay I. Smith
(http://www.cs.otago.ac.nz/cosc453/student_tutorials/princ
ipal_components.pdf) and made parallalelizable to reduce
calculation time. 1,646,535 SMILES (0.17% of GDB-13)
dropped out during the MQN-determination process.
CBDMQN calculations were computed at approximately
175,000 comparisons per minute per CPU.
Substructure fingerprints
For substructure similarity calculation a Daylight-
type 1,024-bit hashed fingerprint from ChemAxon was
used. TSF-similarity calculations were computed at
approximately 86,000 comparisons per minute per
CPU.
Fig. 7 For all 15 bioactive
compounds: Scatter plot of
ROCS TanimotoCombo score
vs. substructure fingerprint
Tanimoto (TSF) of the 10’000
CBDMQN-nearest neighbors and
10’000 randomly selected
compounds from GDB-13
(= 20’000 data points per plot).
Color of the points is according
to CBDMQN to reference:
red = 0–5, orange =
6–15, yellow = 16–30,
green = 31–50, blue C 50.
Levels in the plot are overlayed
with priority red [ orange
[ yellow [ green [ blue
Fig. 8 Structural formula of the 15 reference bioactive compounds and
their analogs with their CBDMQN, ROCS-score and TSF-score relative to
the reference drug. The analogs are not yet known with the following
exceptions: a known; b purchasable; c known as substructure
c
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ROCS
For the ROCS calculations, the stereo information of the 15
reference bioactive compounds was added as found in
DrugBank or Pubchem (see Fig. 7, no information found
for Chlorphenesin, Mexiletine and Phenmetrazine). All
queries and target molecules were sent to Omega to create
a maximum of 200 lowest energy 3D structures including
various stereoisomers and their conformers. For all ROCS
runs the ‘‘TanimotoCombo’’ overlap score was used.
ROCS TanimotoCombo score calculations were computed
at approximately 15 comparisons per minute per CPU.
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